EcoR1’s SPAC Panacea Acquisition prices $125 million IPO at $10

EcoR1’s SPAC Panacea Acquisition prices $125 million IPO at $10

Panacea Acquisition, a blank check company formed by EcoR1 Capital targeting the biotech industry, rai

SPAC Mountain Crest Acquisition files for a $50 million IPO
Special Purpose Acquisition Companies (SPACs) Business Combinations Supported by Nasdaq
Best World eyes purchase of entire stake in British beauty firm Pedal Pulses, Companies & Markets

Panacea Acquisition, a blank check company formed by EcoR1 Capital targeting the biotech industry, raised $125 million by offering 12.5 million units at $10.

Each unit consists of one share of common stock and one-third of a warrant; whole warrants are exercisable at $11.50. EcoR1 Capital has committed to buy $25 million in units at the closing of a proposed acquisition in a forward purchase agreement. At pricing, the SPAC commands a market cap of $161 million. Primary shareholders include an affiliate of EcoR1 Capital and Cowen.

Panacea Acquisition plans to list on the NYSE under the symbol PANA.U. Cowen acted as lead manager on the deal.

Screen for upcoming and completed SPACs with IPO Pro.

The SPAC is led by CEO and Chairman Oleg Nodelman, the founder and Portfolio Manager of San Francisco-based biotech venture firm EcoR1 Capital. The SPAC’s other officers all hold roles at EcoR1, and several of its directors are associated with EcoR1 portfolio companies.

EcoR1 has been a venture investor on several 2020 biotech IPOs, including Avidity Biosciences (RNA; +57% from IPO), ORIC Pharmaceuticals (ORIC; +111%), and Akouos (AKUS; +32%).

Panacea…

Click here for the full story.

COMMENTS

WORDPRESS: 0
DISQUS: